Comments on: Multidrug resistance-associated protein (MRP) expression is correlated with expression of aberrant p53 protein in colorectal cancer, Fukushima Y, Oshika Y, Tokunaga T, et al., Eur J Cancer 1999, 35, 935-938. Mutant p53 and high expression of MRP are associated in acute myeloblastic leukaemia

European Journal of Cancer

Volumn 36, Issue 2, 2000, Pages 270-271

  Turzanski, J ^a   Zhu, Y M ^a   Pallis, M J ^a   Russell, N H ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN; PROTEIN P53;

ACUTE MYELOBLASTIC LEUKEMIA; COLORECTAL CANCER; GENE MUTATION; HUMAN; LETTER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

COLORECTAL NEOPLASMS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; NEOPLASM PROTEINS; P-GLYCOPROTEIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033974414     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00286-5     Document Type: Letter

References (8)

1. Fukushima Y, Oshika Y, Tokunaga T, et al. Multidrug resistance-associated protein (MRP) expression is correlated with expression of aberrant p53 protein in colorectal cancer. Eur J Cancer 1999, ISA, 935-938.
2. Zhu Y-M, Das-Gupta EP, Russell NH. Microsatellite instability and p53 mutations are associated with abnormal expression of the MSH2 gene in adult acute leukaemia. Blood 1999, 94(2), 733-740.
3. Pallis M, Turzanski J, Russell NH. Blast maturity and CD34 expression determine the effects of the differentiating agents KH1060 and 9-c/s-retinoic acid on the differentiation and clonogenicity of non-M3 acute myeloid leukaemia cells. Leukaemia 1998, 12(11), 1741-1748.
4. Pallis M, Turzanski J, Harrison G, et al. Use of standardized flow cytometric determinants of multidrug resistance to analyse response to remission induction chemotherapy in patients with acute myeloid leukaemia. BY J Haematol 1999, 104(2), 307-312.
5. Pallis M, Turzanski J, Langabeer S, Russell NH. Reproducible flow cytometric methodology for measuring multidrug resistance in leukaemic blasts. Advances in experimental medicine and biology: vol 457, drug resistance in leukaemia and lymphoma III. NY, USA, Plenum Publishers, 1999, 77-88.
6. Oshika Y, Nakamura M, Tokunaga T, et al. Multidrug resistance-associated protein and mutant p53 protein expression in non-small cell lung cancer. Mod Pathol 1998, 11, 1059-1063.
7. Wang QT, Beck WT. Transcriptional suppression of multidrug resistance-associated protein (MRP) gene expression by wild-type p53. Cancer Res 1998, 58(24), 5762-5769.
8. Endo K, Maehara Y, Ichiyoshi Y, et al. Multidrug resistanceassociated protein expression in clinical gastric carcinoma. Cancer 1996, 77(8), 1681-1687.